牛皮关节炎的生物疗法的持久性:叙述性审查
Magdalena Jasmen1, Dominga García2, Sebastián Ibáñez2
1From the Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
概括
牛皮性关节炎的生物药物持续性有很大的差异,影响治疗结果. 诸如女性性别和并发症等因素增加了非持久性,需要制定改善长期坚持的策略.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 药物持续性对于长期的牛皮关节炎 (PsA) 管理至关重要,影响疗效,安全性和患者满意度.
- 不持久性增加了医疗保健成本,并对发病率和死亡率产生了负面影响.
- 了解持久性模式是优化PsA治疗策略的关键.
研究的目的:
- 审查和综合关于PsA生物疗法药物持久性的数据.
- 在接受生物治疗的PsA患者中确定与非持久性相关的因素.
主要方法:
- 对有关牛皮关节炎中生物药物持久性的现有文献进行系统审查.
- 对各种生物药物类别报告的1年持久率的分析.
- 确定与不持续性相关的患者和治疗相关因素.
主要成果:
- 在PsA中生物药物的1年持久率范围广泛 (37%-73%).
- 特定的药物类别显示出可变的持久性:TNF抑制剂 (32%-85%),IL-12/23和IL-23抑制剂 (25%-89%),IL-17和JAK抑制剂 (51%-77%).
- 女性性别和更高的并发症负担与非持续性风险的增加有关.
结论:
- 报告的持久率的显著变化凸显了对标准化方法的需求.
- 解决不持久性因素对于提高牛皮关节炎的长期治疗结果至关重要.
- 需要进一步的研究,以充分阐明影响PsA生物持久性的因素.
更多相关视频
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
114
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
114
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:26Psychosis: Goals of Pharmacotherapy
104
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
104
01:24T Cell Types and Functions
954
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
954
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K